Association between complete or near complete resolution of psoriasis and improvements in health related quality of life, itching and skin pain: An integrated subanalysis of UNCOVER-2 and UNCOVER-3 - 21/04/16
Andrew Blauvelt, MD, Oregon Medical Research Center, Portland, OR, United States; Christopher Griffiths, MD, University of Manchester, Manchester, United Kingdom; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Lluis Puig, MD, Hospital de Sant Pau, Barcelona, Spain; Emily Heredia, MPH, Eli Lilly and Co, Indianapolis, IN, United States; Russel Burge, MS, Eli Lilly and Co, Indianapolis, IN, United States; Lu Zhang, PhD, Eli Lilly and Co, Indianapolis, IN, United States; Baojin Zhu, PhD, Eli Lilly and Co, Indianapolis, IN, United States; Lotus Mallbris, MD, PhD, Eli Lilly and Co, Indianapolis, IN, United States; Kristian Reich, MD, Dermatologikum Hamburg, Hamburg, Germany
Le texte complet de cet article est disponible en PDF.| Supported 100% by Eli Lilly and Co. |
Vol 74 - N° 5S1
P. AB237 - mai 2016 Retour au numéro
Article précédent
- Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis
- Association between tumor necrosis factor inhibitor therapy and reduced risk of major adverse cardiovascular events in patients with psoriasis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?